Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gregory A. Rufener"'
Autor:
Brian G. Till, Stanley R. Riddell, David G. Maloney, Damian J. Green, Jeffrey K. Rossow, Lihua E. Budde, Barbara Pender, Ajay K. Gopal, Michael C. Jensen, Sang Yun Lee, Philip Olsen, Oliver W. Press, Gregory A. Rufener
CD20 is an attractive immunotherapy target for B-cell non-Hodgkin lymphomas, and adoptive transfer of T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD20 is a promising strategy. A theoretical limitation is that r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce1813c46f07193be5c47a664c6df0b3
https://doi.org/10.1158/2326-6066.c.6548539.v1
https://doi.org/10.1158/2326-6066.c.6548539.v1
Autor:
Lihua E. Budde, Philip Olsen, Jeffrey K. Rossow, Sang Yun Lee, Barbara S. Pender, David G. Maloney, Gregory A. Rufener, Damian J. Green, Brian G. Till, Stanley R. Riddell, Ajay K. Gopal, Oliver W. Press, Michael C. Jensen
Publikováno v:
Cancer Immunology Research. 4:509-519
CD20 is an attractive immunotherapy target for B-cell non-Hodgkin lymphomas, and adoptive transfer of T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD20 is a promising strategy. A theoretical limitation is that r
Autor:
Shaunda A. Brouns, Gregory A. Rufener, Brian G. Till, David G. Maloney, Michael C. Jensen, Lihua E. Budde, Oliver W. Press
Publikováno v:
Blood. 120:4222-4222
Abstract 4222 BACKGROUND: Adoptive cellular therapy using autologous T cells that have been genetically modified to express a chimeric antigen receptor (CAR) has emerged as a promising therapy for lymphoma. Clinical trials for lymphoid malignancies t